Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures

[1]  L. Defebvre,et al.  Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation , 2011, Neurobiology of Aging.

[2]  A. Lang,et al.  Translational research in neurology and neuroscience 2011: movement disorders. , 2011, Archives of neurology.

[3]  Ying Sun,et al.  Acid β‐glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter α‐synuclein processing , 2011, Annals of neurology.

[4]  J. Angel,et al.  IL‐7‐dependent STAT‐5 activation and CD8+ T cell proliferation are impaired in HIV infection , 2011, Journal of leukocyte biology.

[5]  K. Jellinger.  Changing concepts in Parkinson's disease Glenda Halliday Roger , 2011, The Lancet Neurology.

[6]  M. Kubo,et al.  LRRK2 is expressed in B-2 but not in B-1 B cells, and downregulated by cellular activation , 2010, Journal of Neuroimmunology.

[7]  Mark R. Cookson,et al.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease , 2010, Nature Reviews Neuroscience.

[8]  Michael Weisman,et al.  Association of Variants at 1q32 and STAT3 with Ankylosing Spondylitis Suggests Genetic Overlap with Crohn's Disease , 2010, PLoS genetics.

[9]  Mark J Daly,et al.  LRRK2 Is Involved in the IFN-γ Response and Host Response to Pathogens , 2010, The Journal of Immunology.

[10]  V. Dixit,et al.  Manipulation of host cell death pathways during microbial infections. , 2010, Cell host & microbe.

[11]  M. Huang,et al.  Inflammasome inhibition as a pathogenic stealth mechanism. , 2010, Cell host & microbe.

[12]  Z. Berger,et al.  Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. , 2010, Biochemistry.

[13]  R. J. Kelleher,et al.  Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice , 2010, Proceedings of the National Academy of Sciences.

[14]  D. Ojcius,et al.  Aspergillus fumigatus Stimulates the NLRP3 Inflammasome through a Pathway Requiring ROS Production and the Syk Tyrosine Kinase , 2010, PloS one.

[15]  D. Dickson,et al.  Leucine-Rich Repeat Kinase 2 Gene-Associated Disease: Redefining Genotype-Phenotype Correlation , 2010, Neurodegenerative Diseases.

[16]  M. Kubo,et al.  Age-dependent and cell-population-restricted LRRK2 expression in normal mouse spleen. , 2010, Biochemical and biophysical research communications.

[17]  David S. Park,et al.  DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway , 2010, Proceedings of the National Academy of Sciences.

[18]  P. Gros,et al.  A common genetic fingerprint in leprosy and Crohn's disease? , 2009, The New England journal of medicine.

[19]  Ying Wang,et al.  Genomewide association study of leprosy. , 2009, The New England journal of medicine.

[20]  Jie Shen,et al.  α-Synuclein and LRRK2: Partners in Crime , 2009, Neuron.

[21]  David S. Park,et al.  Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. , 2009, Human molecular genetics.

[22]  Richard Wade-Martins,et al.  LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. , 2009, Human molecular genetics.

[23]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[24]  N. Greig,et al.  Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases. , 2009, Mini-Reviews in Medical Chemistry.

[25]  J. Satsangi,et al.  The genetics of Crohn's disease. , 2009, Annual review of genomics and human genetics.

[26]  A. Pisani,et al.  R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice , 2009, Proceedings of the National Academy of Sciences.

[27]  D. Philpott,et al.  Role of Nod1 in Mucosal Dendritic Cells during Salmonella Pathogenicity Island 1-Independent Salmonella enterica Serovar Typhimurium Infection , 2009, Infection and Immunity.

[28]  A. Singleton,et al.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.

[29]  F. Takken,et al.  To Nibble at Plant Resistance Proteins , 2009, Science.

[30]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[31]  A. Paetau,et al.  Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo , 2009, Molecular Brain.

[32]  M. Cookson,et al.  Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions , 2009, ASN neuro.

[33]  E. Hirsch,et al.  Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. , 2008, The Journal of clinical investigation.

[34]  H. Melrose.  Update on the functional biology of Lrrk2. , 2008, Future neurology.

[35]  P. Ferenci,et al.  Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C , 2008, Alimentary pharmacology & therapeutics.

[36]  A. Eklund,et al.  GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein , 2008, Proceedings of the National Academy of Sciences.

[37]  Judy H. Cho,et al.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.

[38]  T. Dawson,et al.  Dynamic and redundant regulation of LRRK2 and LRRK1 expression , 2007, BMC Neuroscience.

[39]  C. Klein,et al.  Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder , 2007, Neurology.

[40]  Honglei Chen,et al.  Peripheral Inflammatory Biomarkers and Risk of Parkinson's Disease , 2007 .

[41]  D. Philpott,et al.  Nod1 and Nod2 induce CCL5/RANTES through the NF‐κB pathway , 2007 .

[42]  L. Racacho,et al.  LRRK2 Screening in a Canadian Parkinson's Disease Cohort , 2007, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[43]  Sylvie Faucher,et al.  Involvement of Interferon-γ in Microglial-Mediated Loss of Dopaminergic Neurons , 2007, The Journal of Neuroscience.

[44]  I. Marín.  The Parkinson disease gene LRRK2: evolutionary and structural insights. , 2006, Molecular biology and evolution.

[45]  L. Abel,et al.  Genetic predisposition to leprosy: A major gene reveals novel pathways of immunity to Mycobacterium leprae. , 2006, Seminars in immunology.

[46]  Tetsuaki Arai,et al.  LRRK2 Expression in Normal and Pathologic Human Brain and in Human Cell Lines , 2006, Journal of neuropathology and experimental neurology.

[47]  Matthew J. Farrer,et al.  LRRK2 in Parkinson's disease: protein domains and functional insights , 2006, Trends in Neurosciences.

[48]  O. Sydow,et al.  LRRK2 expression linked to dopamine‐innervated areas , 2006, Annals of neurology.

[49]  M. Farrer,et al.  LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? , 2006, Trends in molecular medicine.

[50]  Christine Klein,et al.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. , 2006, The New England journal of medicine.

[51]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Michael Karin,et al.  Nod2 Mutation in Crohn's Disease Potentiates NF-κB Activity and IL-1ß Processing , 2005, Science.

[53]  J. Casanova,et al.  Genetic dissection of immunity in leprosy. , 2005, Current opinion in immunology.

[54]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[55]  D. Philpott,et al.  Toll‐like receptor 2‐dependent bacterial sensing does not occur via peptidoglycan recognition , 2004, EMBO reports.

[56]  M. Newport,et al.  Polymorphism in NOD2, Crohn's disease, and susceptibility to pulmonary tuberculosis. , 2004, FEMS immunology and medical microbiology.

[57]  E. Buschman,et al.  Linkage of leprosy susceptibility to Parkinson's disease genes. , 2004, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[58]  H. Braak,et al.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.

[59]  B. Hyman,et al.  Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. , 2002, The American journal of pathology.

[60]  Judy H. Cho,et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.

[61]  Michael Weisman,et al.  Association of Variants at 1 q 32 and STAT 3 with Ankylosing Spondylitis Suggests Genetic Overlap with Crohn ’ s Disease , 2010 .

[62]  D. Philpott,et al.  Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry , 2010, Nature Immunology.

[63]  M. Netea,et al.  Genomewide association study of leprosy. , 2010, The New England journal of medicine.

[64]  David S. Park,et al.  Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[65]  D. Philpott,et al.  Nod1 and Nod2 induce CCL5/RANTES through the NF-kappaB pathway. , 2007, European journal of immunology.

[66]  M. Schlossmacher,et al.  Parkinson's disease: assays for the ubiquitin ligase activity of neural Parkin. , 2005, Methods in molecular biology.